GlassScriptPhysician profile
Gerald R Miceli
NPI 1396705570
$4,613.53
in general payments reported to CMS, 2019-2025
30 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $239 · 2021: $555 · 2022: $779 · 2023: $1,066 · 2024: $1,508 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Travel and Lodging: $440 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.62 |
| Travel and Lodging | $439.88 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $942.66 | 2021-2025 | Minimed 780g, Closurefast |
| Insulet Corporation | $654.06 | 2019-2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $487.76 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $466.30 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $383.84 | 2019-2024 | |
| Amgen INC. | $259.37 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Xeris Pharmaceuticals, INC. | $206.27 | 2021-2024 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $177.18 | 2022-2023 | Strensiq |
| Glaxosmithkline, LLC. | $139.24 | 2022-2024 | Benlysta, Shingrix |
| Ascensia Diabetes Care US INC. | $111.80 | 2019-2024 | |
| Shire North American Group INC | $85.09 | 2019 | |
| Kyowa Kirin, INC. | $77.21 | 2023-2024 | Crysvita |
| Lilly USA, LLC | $74.91 | 2019-2022 | |
| Abbott Laboratories | $74.84 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $59.88 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.86 | 2019-2024 | |
| Ucb, INC. | $56.77 | 2023 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $38.56 | 2019-2022 | |
| Rhythm Pharmaceuticals, INC. | $32.74 | 2021 | |
| Corcept Therapeutics | $32.10 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $26.91 | 2025 | |
| Radius Health, INC. | $25.95 | 2020-2023 | |
| Ultragenyx Pharmaceutical INC. | $24.58 | 2022 | |
| Pfizer INC. | $23.73 | 2024 | |
| Companion Medical, INC. | $20.89 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.68 | 2023 | Nuzyra |
| Horizon Therapeutics Plc | $14.23 | 2023 | Krystexxa |
| Exact Sciences Corporation | $13.64 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $12.75 | 2019 | |
| Novo Nordisk INC | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Miceli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.